AKVANO SPRAY DELIVERY SYSTEM FOR TOPICAL APPLICATION CAN BE FINE-TUNED FOR FAST OR SLOW RELEASE
It is a pleasure to share the latest diffusion study results on the AKVANO® drug delivery system developed and owned by our partner Lipidor AB (from now on LIPIDOR).
Results from the new in vitro permeation experiments, which have been performed on ketoprofen, diclofenac diethylamine and diclofenac sodium formulations in AKVANO®, can be seen in this white paper.
AKVANO® is a drug delivery technology based on sprayable formulations consisting of lipid components dissolved in a volatile, water-free solvent mixture. When this formulation is applied to the skin, the solvent evaporates and a non-occlusive lipid layer is formed in an immediate interaction with the skin surface. Earlier studies show that by choosing different lipids in the AKVANO vehicle, the skin barrier could either be strengthened or weakened, made evident by changes in transepidermal water loss (TEWL).
DCAT Week 2018
19/03 - 22/03
New York City, The Lotte New York Palace Hotel
Swiss Venture Club Prix 2015
Cerbios has been awarded second place at the bi-annual Swiss Venture Club Prix.
“This is an important recognition for Cerbios, the founders that created it in the late 70’s, the management and all employees that made this possible” confirms Gabriel Haering, Cerbios’ CEO.
“Being one of the six finalists chosen among 50 companies representing different industrial branches in Ticino was already a great achievement. Reaching the second place among the six finalist is splendid!”
The main criteria for the choice of finalists and winners were the following:
- Innovation as key company value
- Regional presence and impact at different levels
- An excellent track record
- Leadership in the reference market
- Operational sustainability
This award is not only a recognition for Cerbios’ strategy and approach but also a commitment towards the future in order to maintain the high standard achieved.